Compare Stocks: INO, MRNA, EDIT, and RZLT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.93 -0.7%	$2.77	$1.66 ▼ $3.94	$453.06M	2	2.39 million shs	3.22 million shs
INO Inovio Pharmaceuticals	$0.77 -16.9%	$1.15	$0.56 ▼ $2.72	$96.01M	1.61	4.09 million shs	9.57 million shs
MRNA Moderna	$222.76 +4.0%	$180.72	$22.28 ▼ $254.48	$85.50B	1.09	19.82 million shs	10.77 million shs
RZLT Rezolute	$4.12 -2.4%	$4.27	$1.07 ▼ $11.46	$408.20M	0.53	1.67 million shs	756,227 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	-0.68%	+17.67%	+13.13%	+13.57%	-3.62%
INO Inovio Pharmaceuticals	-17.01%	-8.00%	-30.47%	+14.00%	-68.24%
MRNA Moderna	+4.02%	+9.93%	+9.49%	+306.35%	+801.86%
RZLT Rezolute	-2.37%	+6.74%	+0.73%	-12.71%	-56.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.93 -0.7%	$2.77	$1.66 ▼ $3.94	$453.06M	2	2.39 million shs	3.22 million shs
INO Inovio Pharmaceuticals	$0.77 -16.9%	$1.15	$0.56 ▼ $2.72	$96.01M	1.61	4.09 million shs	9.57 million shs
MRNA Moderna	$222.76 +4.0%	$180.72	$22.28 ▼ $254.48	$85.50B	1.09	19.82 million shs	10.77 million shs
RZLT Rezolute	$4.12 -2.4%	$4.27	$1.07 ▼ $11.46	$408.20M	0.53	1.67 million shs	756,227 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	-0.68%	+17.67%	+13.13%	+13.57%	-3.62%
INO Inovio Pharmaceuticals	-17.01%	-8.00%	-30.47%	+14.00%	-68.24%
MRNA Moderna	+4.02%	+9.93%	+9.49%	+306.35%	+801.86%
RZLT Rezolute	-2.37%	+6.74%	+0.73%	-12.71%	-56.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.71	Moderate Buy	$5.83	99.09% Upside
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$3.17	310.30% Upside
MRNA Moderna	2.08	Hold	$107.10	-51.92% Downside
RZLT Rezolute	2.71	Moderate Buy	$11.22	172.38% Upside

Current Analyst Ratings Breakdown

Latest INO, MRNA, EDIT, and RZLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	MRNA Moderna	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Market Perform
10/26/2026	MRNA Moderna	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$167.00 ➝ $230.00
10/23/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell
10/21/2026	MRNA Moderna	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/21/2026	MRNA Moderna	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Hold	$40.00 ➝ $90.00
10/15/2026	RZLT Rezolute	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RZLT Rezolute	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/15/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$120.00 ➝ $137.00
10/13/2026	RZLT Rezolute	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/9/2026	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$170.00 ➝ $200.00

(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$47.01M	9.57	N/A	N/A	$0.28 per share	10.46
INO Inovio Pharmaceuticals	$60K	1,330.07	N/A	N/A	$0.36 per share	2.14
MRNA Moderna	$1.94B	45.75	N/A	N/A	$22.14 per share	10.06
RZLT Rezolute	N/A	N/A	N/A	N/A	$1.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/6/2026 (Estimated)
RZLT Rezolute	-$77.59M	-$0.76	N/A	N/A	N/A	N/A	-62.99%	-57.94%	11/5/2026 (Estimated)

Latest INO, MRNA, EDIT, and RZLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	INO Inovio Pharmaceuticals	-$0.20	N/A	N/A	N/A	$2.27 million	N/A
11/9/2026	Q3 2026	EDIT Editas Medicine	-$0.21	N/A	N/A	N/A	$4.54 million	N/A
11/6/2026	Q3 2026	MRNA Moderna	-$1.10	N/A	N/A	N/A	$890.25 million	N/A
11/5/2026	Q1 2027	RZLT Rezolute	-$0.18	N/A	N/A	N/A	$1.12 million	N/A
9/24/2026	Q4 2026	RZLT Rezolute	-$0.1479	-$0.20	-$0.0522	-$0.20	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	3.19	3.19
INO Inovio Pharmaceuticals	N/A	1.00	1.00
MRNA Moderna	0.09	2.29	2.18
RZLT Rezolute	N/A	9.68	9.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
INO Inovio Pharmaceuticals	26.79%
MRNA Moderna	75.33%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	3.10%
INO Inovio Pharmaceuticals	1.70%
MRNA Moderna	10.80%
RZLT Rezolute	14.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
INO Inovio Pharmaceuticals	112	103.40 million	101.64 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
RZLT Rezolute	58	96.73 million	82.43 million	Optionable

INO, MRNA, EDIT, and RZLT Headlines

Recent News About These Companies

Rezolute (RZLT) Projected to Post Quarterly Earnings on Thursday

October 29 at 4:10 AM | marketbeat.com

Rezolute (NASDAQ:RZLT) Stock Crosses Below Two Hundred Day Moving Average - Here's What Happened

October 27 at 4:17 AM | americanbankingnews.com

Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average - What's Next?

October 27 at 3:59 AM | marketbeat.com

Rezolute, Inc. (RZLT) Stock Price, News, Quote & History - Yahoo Finance

October 23, 2026 | finance.yahoo.com

Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December

October 15, 2026 | finance.yahoo.com

Rezolute (NASDAQ:RZLT) Stock Rating Cut to Strong Sell at Zacks Research

October 15, 2026 | marketbeat.com

Rezolute Completes Enrollment In Phase 3 UpLIFT Study Of Ersodetug For Tumor Hyperinsulinism

October 15, 2026 | rttnews.com

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

October 14, 2026 | globenewswire.com

Rezolute, Inc. (RZLT) Latest Press Releases & Corporate News - Yahoo Finance

October 8, 2026 | finance.yahoo.com

Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

October 8, 2026 | defenseworld.netD

Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

October 8, 2026 | marketbeat.com

Cantor Fitzgerald upgrades Rezolute to overweight from neutral

October 6, 2026 | msn.com

Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug

October 6, 2026 | msn.com

Rezolute (NASDAQ:RZLT) Stock Price Target Raised at Citizens Jmp

October 6, 2026 | marketbeat.com

Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment

October 5, 2026 | finance.yahoo.com

Rezolute gets FDA nod for pre-BLA meeting despite phase 3 miss — retail expects huge rerating

October 5, 2026 | msn.com

Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying

October 5, 2026 | marketbeat.com

Rezolute Prepares For Potential BLA Filing Of Ersodetug In Congenital HI

October 5, 2026 | rttnews.com

Rezolute receives FDA guidance for ersodetug pre-BLA meeting

October 5, 2026 | grafa.comG

FDA Recommends Next Regulatory Step For Rezolute's Ersodetug;Stock Up

October 5, 2026 | rttnews.com

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

October 5, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INO, MRNA, EDIT, and RZLT Company Descriptions

Editas Medicine NASDAQ:EDIT

$2.93 -0.02 (-0.68%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$2.86 -0.06 (-2.22%)

As of 06:29 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Inovio Pharmaceuticals NASDAQ:INO

$0.77 -0.16 (-16.89%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.08 (+10.91%)

As of 07:40 AM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Moderna NASDAQ:MRNA

$222.76 +8.60 (+4.02%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$218.92 -3.84 (-1.72%)

As of 07:40 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Rezolute NASDAQ:RZLT

$4.12 -0.10 (-2.37%)

Closing price 10/29/2026 04:00 PM Eastern

Extended Trading

$4.17 +0.05 (+1.29%)

As of 07:00 AM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, EDIT, and RZLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, EDIT, and RZLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, EDIT, and RZLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, EDIT, and RZLT Company Descriptions

Editas Medicine NASDAQ:EDIT

Inovio Pharmaceuticals NASDAQ:INO

Moderna NASDAQ:MRNA

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INO, MRNA, EDIT, and RZLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INO, MRNA, EDIT, and RZLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INO, MRNA, EDIT, and RZLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INO, MRNA, EDIT, and RZLT Company Descriptions

Editas Medicine NASDAQ:EDIT

Inovio Pharmaceuticals NASDAQ:INO

Moderna NASDAQ:MRNA

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools